These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37362321)

  • 1. Successes in antiviral drug discovery: a tribute to Nick Meanwell.
    Rotella DP
    Med Chem Res; 2023 Jun; ():1-10. PubMed ID: 37362321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation.
    Nakata M; Tang W
    Drug Discov Ther; 2008 Oct; 2(5):262-3. PubMed ID: 22504718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hepatitis C: perspectives.
    Pol S; Corouge M
    Med Mal Infect; 2014 Oct; 44(10):449-54. PubMed ID: 25174659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
    Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in the discovery of agents to treat hepatitis C.
    Rönn R; Sandström A
    Curr Top Med Chem; 2008; 8(7):533-62. PubMed ID: 18473882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus.
    Tavares RCF; de Castro Amaral Feldner AC; Pinho JRR; de Mello Malta F; Carvalho-Filho RJ; Santana RAF; de Castro VFD; Dastoli GTF; Lima JC; Ferraz MLCG
    Infect Drug Resist; 2018; 11():1993-2000. PubMed ID: 30464541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents.
    Minosse C; Selleri M; Giombini E; Bartolini B; Capobianchi MR; Cerilli S; Loiacono L; Taibi C; D'Offizi G; McPhee F; Garbuglia A
    Infect Drug Resist; 2018; 11():2117-2127. PubMed ID: 30464554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.
    Bartolini B; Giombini E; Taibi C; Lionetti R; Montalbano M; Visco-Comandini U; D'Offizi G; Capobianchi MR; McPhee F; Garbuglia AR
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28783119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naïve patients from Argentina.
    Martínez AP; García G; Ridruejo E; Culasso AC; Pérez PS; Pereson MJ; Neukam K; Flichman D; Di Lello FA
    J Med Virol; 2019 Nov; 91(11):1970-1978. PubMed ID: 31273794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of chronic viral hepatitis C with direct acting antiviral agent: review].
    Malov VA; Ubeeva EA; Ubeeva IP; Nikolaev SM; Umbetova KT
    Ter Arkh; 2019 Nov; 91(11):86-89. PubMed ID: 32598617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review.
    Akram M; Tahir IM; Shah SMA; Mahmood Z; Altaf A; Ahmad K; Munir N; Daniyal M; Nasir S; Mehboob H
    Phytother Res; 2018 May; 32(5):811-822. PubMed ID: 29356205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
    Tornai I
    Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.
    Court JJ; Poisson C; Ardzinski A; Bilimoria D; Chan L; Chandupatla K; Chauret N; Collier PN; Das SK; Denis F; Dorsch W; Iyer G; Lauffer D; L'Heureux L; Li P; Luisi BS; Mani N; Nanthakumar S; Nicolas O; Rao BG; Ronkin S; Selliah S; Shawgo RS; Tang Q; Waal ND; Yannopoulos CG; Green J
    J Med Chem; 2016 Jul; 59(13):6293-302. PubMed ID: 27366941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV Protease: Historical Perspective and Current Research.
    Weber IT; Wang YF; Harrison RW
    Viruses; 2021 May; 13(5):. PubMed ID: 34066370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015).
    Ivanenkov YA; Aladinskiy VA; Bushkov NA; Ayginin AA; Majouga AG; Ivachtchenko AV
    Expert Opin Ther Pat; 2017 Apr; 27(4):401-414. PubMed ID: 27967269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.
    Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA
    Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.